Mood stabilizers such as lithium and valproate, both commonly used in the treatment of bipolar disorder, modulate circadian rhythms via inhibition of glycogen-synthase-kinase-3-beta (GSK3Beta), which phosphorylates the cycle length determining PER clock gene products. Here, GSK3B is linked to bipolar disorder.